대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	A Change in Insulin Sensitivity and Lipid Profile in Renal Transplant Recipients Converted from Cyclosporine or Standard Release Tacrolimus to Once-daily Prolonged Release Tacrolimus
저자	Joung Wook Yang1, Soo Young Kim1, Ye Na Kim1, Ho Sik Shin1, Yeon Soon Jung1, Hark Rim1, Hyun Yul Rhew2
출판정보	2015; 2015(1):
키워드	사이클로스포린,타크로리무스,인슐린 감수성
초록	Background: New-onset diabetes after transplantation may be associated with the use of tacrolimus (Tac) causing impaired insulin release or reduced insulin sensitivity. And, dyslipidemia commonly occurred after transplantation. Such effects in insulin sensitivity and lipid profile have not been studied in renal transplant recipients receiving traditional twice-daily tacrolimus (TacBID) or cyclosporine and then compared to the new once-daily prolonged release formulation of tacrolimus (TacOD). Methods: We performed an observational prospective study of 20 stable non-diabetic renal transplant recipients on change in insulin sensitivity and lipid profile in renal transplant recipients converted from cyclosporine or standard release tacrolimus to once-daily prolonged release tacrolimus. We evaluated the level of HbA1c, total cholesterol, HDL, LDL, TG, apolipoprotein A1, apolipoprotein B, serum creatinine, fasting plasma glucose, fasting insulin and HOMA-β at base line, two and four months. To analyze differences in parameter, we performed a t-test in both groups (cyclosporine to TacOD conversion group/TacBID to TacOD conversion group) Results: Tacrolimus trough concentration was 4.5±0.5 μg/mL. The result did not showed and any change in insulin sensitivity and lipid profile after conversion at two and four months. Conclusion: Conversion from standard TacBID or cyclosporine to TacOD is safe. In spite of a reduced Tac exposure, there was no change in insulin sensitivity and lipid profile in renal transplant recipients.
원문(PDF)	PDF 원문보기

목록

위로가기